After considering the feedback from consultation, the appraisal committee has prepared final draft guidance (FDG) on olaparib in combination with bevacizumab for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy with bevacizumab and submitted it to NICE.

The FDG has been sent to consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it and/or notify us of any factual errors.  The FDG has been sent to commentators for information, who can consider notifying us of any factual errors only. Subject to any appeal by consultees, the FDG may be used as the basis for NICE's guidance on the use of the appraised technology in the NHS in England.

Please note that the appeal period for this appraisal will close at 5pm, Thursday 21 December 2023.

This page was last updated: